TABLE OF CONTENTS

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 DEFINITION 22
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY 24
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.2 SECONDARY DATA 27
2.2.1 SECONDARY SOURCES 27
2.3 PRIMARY DATA 28
2.3.1 KEY DATA FROM PRIMARY SOURCES 28
2.3.2 KEY INDUSTRY INSIGHTS 29
2.4 MARKET SIZE ESTIMATION 30
2.4.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 30
2.4.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 31
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.6 ASSUMPTIONS FOR THE STUDY 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 39
4.1 ATTRACTIVE OPPORTUNITIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET 39
4.2 OLIGONUCLEOTIDES SYNTHESIS MARKET, BY SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS 40
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SYNTHESIZED OLIGONUCLEOTIDES TYPE 40
4.4 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY RESEARCH APPLICATION AND COUNTRY 41
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY THERAPEUTIC APPLICATION 42
4.6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 43
4.7 GEOGRAPHIC SNAPSHOT: OLIGONUCLEOTIDE SYNTHESIS MARKET 44
 
5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DRIVERS 46
5.2.1 INCREASING USE OF SYNTHESIZED OLIGONUCLEOTIDES IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS 46
5.2.2 INCREASING GOVERNMENT INVESTMENTS AND R&D EXPENDITURE IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 47
5.2.3 RISE IN VENTURE CAPITAL INVESTMENTS 48
5.3 MARKET RESTRAINTS 48
5.3.1 PRICE EROSION OF SYNTHESIZED OLIGONUCLEOTIDES 48
5.3.2 LACK OF A UNIFIED SET OF REGULATIONS FOR THERAPEUTIC OLIGONUCLEOTIDES 48
5.4 MARKET OPPORTUNITIES 49
5.4.1 EMERGING ASIAN MARKETS 49
5.5 MARKET CHALLENGES 50
5.5.1 LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES 50
5.5.2 DELIVERY OF OLIGONUCLEOTIDE DRUGS TO SPECIFIC TARGETS 50
5.6 INDUSTRY TRENDS 51
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 52
6.1 INTRODUCTION 53
6.2 SYNTHESIZED OLIGONUCLEOTIDES 54
6.2.1 BY PRODUCT 57
6.2.1.1 Primers 57
6.2.1.2 Probes 60
6.2.1.3 Large-scale synthesis oligonucleotides 63
6.2.1.4 Intermediate-scale synthesis oligonucleotides 65
6.2.1.5 Linkers & Adaptors 68
6.2.2 BY TYPE 70
6.2.2.1 Custom oligonucleotides 71
6.2.2.2 Pre-designed oligonucleotides 74
6.3 REAGENTS 76
6.4 EQUIPMENT 79
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 82
7.1 INTRODUCTION 83
7.2 RESEARCH 84
7.2.1 PCR 87
7.2.2 QPCR 89
7.2.3 SEQUENCING 91
7.2.4 GENE SYNTHESIS 93
7.2.5 OTHER RESEARCH APPLICATIONS 96
7.3 DIAGNOSTICS 98
7.4 THERAPEUTICS 101
7.4.1 RNAI 104
7.4.2 NUCLEIC ACID APTAMERS 107
7.4.3 DNA/ANTISENSE OLIGONUCLEOTIDES 109
7.4.4 IMMUNOTHERAPY APPLICATIONS 112
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 115
8.1 INTRODUCTION 116
8.2 ACADEMIC RESEARCH INSTITUTES 117
8.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 120
8.4 DIAGNOSTIC LABORATORIES 123
8.5 OTHER END USERS 125
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 128
9.1 INTRODUCTION 129
9.2 NORTH AMERICA 130
9.2.1 US 135
9.2.2 CANADA 139
9.3 EUROPE 143
9.3.1 GERMANY 149
9.3.2 FRANCE 153
9.3.3 UK 157
9.3.4 REST OF EUROPE (ROE) 161
9.4 ASIA PACIFIC (APAC) 166
9.4.1 CHINA 171
9.4.2 JAPAN 175
9.4.3 INDIA 179
9.4.4 REST OF ASIA PACIFIC (ROAPAC) 183
9.5 LATIN AMERICA 188
9.5.1 BRAZIL 193
9.5.2 MEXICO 194
9.5.3 REST OF LATIN AMERICA 196
9.6 MIDDLE EAST & AFRICA 198
10 COMPETITIVE LANDSCAPE 203
10.1 OVERVIEW 203
10.2 MARKET SHARE ANALYSIS 204
10.3 COMPETITIVE SCENARIO 207
10.3.1 PARTNERSHIPS, AGREEMENTS, CONTRACTS, AND COLLABORATIONS 207
10.3.2 PRODUCT LAUNCHES, UPGRADES, AND APPROVALS 207
10.3.3 EXPANSIONS 208
10.3.4 ACQUISITIONS 209
11 COMPANY PROFILES 210
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View)*
11.1 INTEGRATED DNA TECHNOLOGIES 210
11.2 MERCK KGAA 216
11.3 EUROFINS GENOMICS 222
11.4 THERMO FISHER SCIENTIFIC 226
11.5 BIOAUTOMATION 230
11.6 AGILENT TECHNOLOGIES 233
11.7 EUROGENTEC 241
11.8 GE HEALTHCARE 245
11.9 LGC BIOSEARCH TECHNOLOGIES 249
11.10 NITTO DENKO AVECIA 251
11.11 GENSCRIPT 254
11.12 GENEDESIGN (PART OF AJINOMOTO) 257
11.13 TRILINK BIOTECHNOLOGIES (PART OF MARAVAI LIFESCIENCES) 259
11.14 BIO-SYNTHESIS 261
11.15 ATDBIO 263
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View might not be captured in case of unlisted companies.
12 APPENDIX 264
12.1 INSIGHTS FROM INDUSTRY EXPERTS 264
12.2 DISCUSSION GUIDE 265
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 268
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 270
12.5 AVAILABLE CUSTOMIZATIONS 270
12.6 RELATED REPORTS 271
12.7 AUTHOR DETAILS 272